| |
| Issue |
Title |
| |
| Vol 16, No 3S (2022) |
Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system |
Abstract
PDF (Rus)
|
|
A. Yu Kulikov, V. G. Serpik, A. M. Lila |
| |
| Vol 15, No 1 (2021) |
Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system |
Abstract
PDF (Rus)
|
|
E. A. Pyadushkina, E. V. Derkach, M. Yu. Frolov, V. A. Rogov, A. S. Salasyuk |
| |
| Vol 15, No 1 (2021) |
Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis |
Abstract
PDF (Rus)
|
|
R. O. Dreval |
| |
| Vol 13, No 4S (2019) |
Comparative clinical and economic analysis of the use of symptomatic slow-acting drugs containing glucosamine sulfate in patients with Stage II gonarthrosis during outpatient care |
Abstract
PDF (Rus)
|
|
I. V. Sarvilina, Yu. S. Prokofyeva |
| |
| Vol 12, No 3 (2018) |
Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation |
Abstract
PDF (Rus)
|
|
A. M. Lila, R. О. Dreval, V. V. Shipitsyn |
| |
| Vol 11, No 2 (2017) |
Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis |
Abstract
PDF (Rus)
|
|
S. K. Zyryanov, I. N. Dyakov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk |
| |
| Vol 8, No 3 (2014) |
Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis |
Abstract
PDF (Rus)
|
|
I. I. Dyakov, D. V. Goryachev |
| |
| 1 - 7 of 7 Items |
|
